Close
  Indian J Med Microbiol
 

Figure 1: Mean progression-free survival in patients on lorlatinib of 9.6 months (range: 7.1–12.1 months) (number of events – 15)

Figure 1: Mean progression-free survival in patients on lorlatinib of 9.6 months (range: 7.1–12.1 months) (number of events – 15)